BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1571 related articles for article (PubMed ID: 30142454)

  • 1. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
    Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
    Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formononetin alleviates hepatic steatosis by facilitating TFEB-mediated lysosome biogenesis and lipophagy.
    Wang Y; Zhao H; Li X; Wang Q; Yan M; Zhang H; Zhao T; Zhang N; Zhang P; Peng L; Li P
    J Nutr Biochem; 2019 Nov; 73():108214. PubMed ID: 31520816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
    Hong Y; Choi SI; Hong E; Kim GH
    J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phillygenin ameliorates nonalcoholic fatty liver disease via TFEB-mediated lysosome biogenesis and lipophagy.
    Zhou W; Yan X; Zhai Y; Liu H; Guan L; Qiao Y; Jiang J; Peng L
    Phytomedicine; 2022 Aug; 103():154235. PubMed ID: 35716542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hesperetin ameliorates hepatic oxidative stress and inflammation
    Li J; Wang T; Liu P; Yang F; Wang X; Zheng W; Sun W
    Food Funct; 2021 May; 12(9):3898-3918. PubMed ID: 33977953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Swertiamarin ameliorates oleic acid induced lipid accumulation and oxidative stress by attenuating gluconeogenesis and lipogenesis in hepatic steatosis.
    Patel TP; Rawal K; Soni S; Gupta S
    Biomed Pharmacother; 2016 Oct; 83():785-791. PubMed ID: 27490779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ajugol enhances TFEB-mediated lysosome biogenesis and lipophagy to alleviate non-alcoholic fatty liver disease.
    Zhang H; Lu J; Liu H; Guan L; Xu S; Wang Z; Qiu Y; Liu H; Peng L; Men X
    Pharmacol Res; 2021 Dec; 174():105964. PubMed ID: 34732369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzbromarone aggravates hepatic steatosis in obese individuals.
    Sun P; Zhu JJ; Wang T; Huang Q; Zhou YR; Yu BW; Jiang HL; Wang HY
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2067-2077. PubMed ID: 29526820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis.
    Siculella L; Tocci R; Rochira A; Testini M; Gnoni A; Damiano F
    Biochim Biophys Acta; 2016 May; 1861(5):471-81. PubMed ID: 26869449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chloroform extract of Cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats.
    Lin Z; Wu ZF; Jiang CH; Zhang QW; Ouyang S; Che CT; Zhang J; Yin ZQ
    Phytomedicine; 2016 Nov; 23(12):1475-1483. PubMed ID: 27765368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quercetin alleviates ethanol-induced hepatic steatosis in L02 cells by activating TFEB translocation to compensate for inadequate autophagy.
    Zhao X; Xue X; Wang J; Dai S; Peng C; Li Y
    Phytother Res; 2023 Jan; 37(1):62-76. PubMed ID: 36131369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niga-ichigoside F1 ameliorates high-fat diet-induced hepatic steatosis in male mice by Nrf2 activation.
    Xia SF; Shao J; Zhao SY; Qiu YY; Teng LP; Huang W; Wang SS; Cheng XR; Jiang YY
    Food Funct; 2018 Feb; 9(2):906-916. PubMed ID: 29309075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
    Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
    Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
    He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
    World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the effect of a mixture of two main conjugated linoleic acid isomers on hepatic steatosis in HepG2 cellular model.
    Jalilian A; Golmohammadi T; Meshkani R; Koushki M; Eivazi N; Khorzoughi RB; Fard SRH; Paknejad M
    Mol Biol Rep; 2021 Feb; 48(2):1359-1370. PubMed ID: 33580458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway.
    Zhang Y; Li C; Li X; Wu C; Zhou H; Lu S; Liu X
    Mol Med Rep; 2020 Sep; 22(3):2174-2182. PubMed ID: 32705195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.